Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea Expands Financial Support For Global Innovation Bid

State-Led R&D Grants Rise As New Fund Launches

Executive Summary

While keeping its policy focus mainly on controlling the pandemic situation, South Korea is also increasing R&D grants to support the development of innovative drugs with global blockbuster potential through the launch of renewed and better funded Korea Drug Development Fund.

You may also be interested in...



SCARDA: Japan’s New Vaccine R&D Center With $1.6bn Budget – But Where's The Goal?

Japan has launched a new center to support vaccine and drug projects as a part of a larger scheme to tackle infectious disease. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. 

 

Korea Policies To Shift To Non-COVID Areas In 2022?

The Pink Sheet takes a look back at major policy developments in South Korea in 2021 and ahead at what’s in store for the coming year.

New Data Position Lazertinib As Strong Contender In 1L NSCLC

Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel